PLVAP and neoplasm: Inhibition of PLVAP and ANGPT2 has been shown to suppress tumor growth in mice135, suggesting the potential of FDA-approved antiangiogenic therapies, including anti-VEGF Avastin and anti-ANGPT2 Vabysmo, to intercept preinvasive to invasive disease progression.